Novartis and Ionis Pharmaceuticals announced on September 4, 2026, that their experimental heart drug pelacarsen failed a pivotal Phase 3 clinical trial. The subcutaneous injection missed its primary endpoint of reducing major cardiovascular events in patients with high levels of lipoprotein(a), dealing a surprise blow to the companies’ cardiovascular pipelines.
Pelacarsen Fails to Cut Major Heart Risks in Phase 3 Trial
The drug, named pelacarsen, failed to demonstrate a reduction in severe cardiovascular events—including deaths, heart attacks, and strokes—when compared against a placebo in patients with elevated levels of lipoprotein(a).
The setback occurred in the Phase 3 HORIZON trial, which ran for more than six years and monitored over 8,000 participants. While the trial confirmed that pelacarsen successfully lowered lipoprotein(a) levels, that biological reduction did not translate into a statistically significant drop in clinical heart emergencies.
“These are not the results we hoped for, but they provide important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes.”
Shreeram Aradhye, Chief Medical Officer at Novartis
Novartis executives noted that the comprehensive trial dataset will be formally presented at an upcoming medical congress. The companies have not yet released specific statistical breakdowns, but confirmed that the unexpected outcome arrives at a critical juncture for the Swiss drugmaker’s portfolio.
Market Impact and Pipeline Pressures for Novartis and Ionis
Financial markets reacted swiftly to the trial failure.
The outcome places renewed financial pressure on Novartis as it navigates a wave of patent expirations for key products, including the loss of revenue from its blockbuster heart medication Entresto. Analysts at William Blair had previously estimated that pelacarsen could generate up to $6 billion in peak annual U.S. sales if successful. Before the trial results were announced, Wall Street analysts viewed pelacarsen alongside the anti-inflammatory drug remibrutinib and the gene therapy del-desiran as key multi-billion-dollar growth drivers for the company.
Questions Raised for the Emerging Class of Lp(a) Therapies
Pelacarsen is a monthly subcutaneous injection designed to target lipoprotein(a)—often referred to as Lp(a)—a genetically inherited cholesterol-carrying protein particle linked to increased heart disease risk. According to the American Heart Association, roughly 20% of the global population inherits high levels of Lp(a), leaving patients unable to alter their counts through standard diet and exercise because no approved treatments specifically target the protein.
The trial failure of pelacarsen marks the first outcomes setback for this emerging drug class, prompting immediate analysis across the pharmaceutical sector. Jefferies analyst Dennis Ding noted in a research note that attention will focus on any correlation between baseline Lp(a) starting levels, the magnitude of the reduction, and any associated clinical benefit. Citi analyst Geoff Meacham suggested that the miss creates uncertainty for the entire therapeutic approach.
“The first dedicated outcomes failure lowers confidence across the class and places greater pressure on later studies to demonstrate that deeper lowering of Lp(a) can produce a clinically meaningful reduction of major cardiovascular events.”
Geoff Meacham, Analyst at Citi
Other major pharmaceutical companies are currently advancing alternative pipeline candidates designed to inhibit Lp(a) through different biological mechanisms. Amgen is developing olpasiran, and Eli Lilly is advancing lepodisiran, both of which are currently in late-stage clinical testing. Following the Novartis announcement, Amgen shares dropped 5% in aftermarket trading as investors weighed the broader class implications reported across the industry.
Related reading